DE69130289T2 - Therapeutische verwendung von actin-bindenden verbindungen - Google Patents

Therapeutische verwendung von actin-bindenden verbindungen

Info

Publication number
DE69130289T2
DE69130289T2 DE69130289T DE69130289T DE69130289T2 DE 69130289 T2 DE69130289 T2 DE 69130289T2 DE 69130289 T DE69130289 T DE 69130289T DE 69130289 T DE69130289 T DE 69130289T DE 69130289 T2 DE69130289 T2 DE 69130289T2
Authority
DE
Germany
Prior art keywords
therapeutic use
binding compounds
actin binding
actin
native
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69130289T
Other languages
English (en)
Other versions
DE69130289D1 (de
Inventor
Thomas Stossel
Stuart Lind
Paul Janmey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Application granted granted Critical
Publication of DE69130289D1 publication Critical patent/DE69130289D1/de
Publication of DE69130289T2 publication Critical patent/DE69130289T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
DE69130289T 1990-04-11 1991-04-11 Therapeutische verwendung von actin-bindenden verbindungen Expired - Lifetime DE69130289T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50721490A 1990-04-11 1990-04-11
PCT/US1991/002553 WO1991015770A1 (en) 1990-04-11 1991-04-11 Therapeutic uses of actin-binding compounds

Publications (2)

Publication Number Publication Date
DE69130289D1 DE69130289D1 (de) 1998-11-05
DE69130289T2 true DE69130289T2 (de) 1999-06-02

Family

ID=24017703

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69130289T Expired - Lifetime DE69130289T2 (de) 1990-04-11 1991-04-11 Therapeutische verwendung von actin-bindenden verbindungen

Country Status (10)

Country Link
US (2) US5260224A (de)
EP (1) EP0526544B1 (de)
JP (2) JP3616392B2 (de)
AT (1) ATE171625T1 (de)
AU (1) AU663050B2 (de)
CA (1) CA2080462C (de)
DE (1) DE69130289T2 (de)
DK (1) DK0526544T3 (de)
ES (1) ES2124702T3 (de)
WO (1) WO1991015770A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2124702T3 (es) * 1990-04-11 1999-02-16 Brigham & Womens Hospital Usos terapeuticos de compuestos que se unen a actina.
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
JP3914272B2 (ja) * 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
JPH09510212A (ja) * 1994-03-11 1997-10-14 メルク エンド カンパニー インコーポレーテッド 肺疾患を処置するための組成物
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
USRE38490E1 (en) 1995-11-16 2004-04-06 Baylor College Of Medicine Method for identifying metastatic sequences
USRE38392E1 (en) 1996-01-30 2004-01-20 Baylor College Of Medicine Method for identifying metastatic sequences
CA2274002A1 (en) 1996-12-04 1998-06-11 The Victoria University Of Manchester Wound healing and treatment of fibrosis
JP2002511748A (ja) * 1997-05-19 2002-04-16 カイロン コーポレイション アポトーシス誘導性ゲルゾリン配列
AU734476B2 (en) * 1997-11-05 2001-06-14 Baylor College Of Medicine Sequences for targeting metastatic cells
EP1062340A2 (de) * 1998-03-13 2000-12-27 The Baylor College of Medicine Zusammensetzungen und verfahren zur behandlung und prophylaxe der metastasen erkrankungen
US6403766B1 (en) 1999-10-15 2002-06-11 Cornell Research Foundation, Inc. Human actin regulatory proteins and methods for detection, diagnosis and treatment of different stages of carcinogenesis
US6806355B2 (en) 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
JP2005508892A (ja) * 2001-08-14 2005-04-07 スタテンズ セーラム インスティテュート Ｇｃ−グロブリンの大規模生産のための精製方法、これにより得られる物質およびそれらの医薬用途
WO2003063690A2 (en) * 2002-01-31 2003-08-07 Baylor College Of Medicine Secreted caveolin as a marker for prostate cancer
US7462491B2 (en) * 2002-01-31 2008-12-09 Baylor College Of Medicine Methods and compositions for diagnosis and monitoring of prostate cancer progression by detection of serum caveolin
WO2003088811A2 (en) * 2002-04-16 2003-10-30 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
US7301020B2 (en) * 2003-06-19 2007-11-27 Wisconsin Alumni Research Foundation Macrolide analogs and methods for identifying same
PL1694342T3 (pl) 2003-11-12 2021-07-05 Trustees Of The University Of Pennsylvania Sposoby zastosowania gelsoliny do leczenia lub zapobiegania posocznicy bakteryjnej
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
WO2005112970A2 (en) * 2004-05-12 2005-12-01 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat infections
CA2578478A1 (en) 2004-08-06 2006-02-16 National Jewish Medical And Research Center Product and process for inhibition of biofilm development
US8440622B2 (en) 2006-03-15 2013-05-14 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel)
PL3279663T3 (pl) 2006-03-15 2022-01-10 The Brigham And Women's Hospital, Inc. Zastosowanie gelsoliny do diagnozowania i leczenia chorób zapalnych
US8753662B2 (en) * 2007-02-15 2014-06-17 National Jewish Health Methods and compositions for the disruption of biofilms
DK2250280T3 (en) 2008-01-25 2015-03-09 Gen Hospital Corp THERAPEUTIC USES OF gelsolin in renal failure
US10112000B2 (en) 2010-07-08 2018-10-30 Asahi Kasei Medical Co., Ltd. Method for reducing amyloid beta concentration in blood

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988010259A1 (en) * 1987-06-19 1988-12-29 Syracuse University Cytochalasin purification methods and compositions
ES2124702T3 (es) * 1990-04-11 1999-02-16 Brigham & Womens Hospital Usos terapeuticos de compuestos que se unen a actina.
JPH09315440A (ja) * 1996-05-29 1997-12-09 Mitsui Petrochem Ind Ltd ラップフィルム収納箱

Also Published As

Publication number Publication date
CA2080462A1 (en) 1991-10-12
ATE171625T1 (de) 1998-10-15
EP0526544B1 (de) 1998-09-30
AU663050B2 (en) 1995-09-28
JPH05506034A (ja) 1993-09-02
US5508265A (en) 1996-04-16
JP3616392B2 (ja) 2005-02-02
ES2124702T3 (es) 1999-02-16
DK0526544T3 (da) 1999-06-21
DE69130289D1 (de) 1998-11-05
US5260224A (en) 1993-11-09
WO1991015770A1 (en) 1991-10-17
CA2080462C (en) 2004-10-26
JP2005041881A (ja) 2005-02-17
AU7751691A (en) 1991-10-30
EP0526544A4 (en) 1993-08-11
EP0526544A1 (de) 1993-02-10

Similar Documents

Publication Publication Date Title
DE69130289T2 (de) Therapeutische verwendung von actin-bindenden verbindungen
DE69228701D1 (de) Fragmente von Prion Proteinen.
ATE77056T1 (de) Antikoerperkomplexe von haptenmodifizierten diagnostischen oder therapeutischen mitteln.
NO873753D0 (no) Periodisk biologisk luftbehandlingsprosess og system for denne.
DE68924928D1 (de) Antikörper gegen latente Proteine von menschlichen Papillomavirus, diagnostische Systeme und Methoden.
DE3650135D1 (de) Proteingewinnung.
DE69410630D1 (de) Vorrichtung zur frühembryonalen in ovo injektion
FR2660757B1 (fr) Procede d'identification ou de dosage de proteines et applications.
DE69624150T2 (de) Lösung zur Konservierung von Organen oder Geweben oder Teilen davon aus Menschen oder Tieren
FI973484A0 (fi) Menetelmä immuunivasteen stimuloimiseksi
DK403384A (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
DE69232483T2 (de) Mycobacteriumprotein und dessen verwendung
GEP19971041B (en) Peptide derivatives exhibiting capability to regulate cell proliferation and methods of inhibition of cell proliferation in human and animals (variants)
DE3852625D1 (de) Vektoren und Verbindungen zur Expression von Zymogen-Formen von menschlichem Protein C.
DK325289D0 (da) Strontiumsalt, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende saltet
NO962596L (no) Nytt tumorsupressorgen
DE69330246D1 (de) Impfstoffe auf der basis von streptokinase
FI885025A (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
KR910004802A (ko) 긴팔원숭이 백혈병 비루스 리셉터 단백질, 이를 암호화하는 단리된 정제 dna 서열 및 이들을 동정하는 방법
DE3855007D1 (de) METHODE ZUR REINIGUNG REKOMBINANTER t-PA VON DEN IHREN ENTSPRECHENDEN WIRTSZELLPROTEINEN
NO872223D0 (no) Bakteriociner og preparater inneholdende disse for anti-virus behandling.
NO882836D0 (no) Fremgangsmaate for kjemisk modifisering av protider (proteiner og peptider).
DE3586795D1 (de) Absorptionsverbesserer fuer proteine.
DE59805440D1 (de) Verwendung von lbp zur sepsistherapie
NO871150D0 (no) Innretning for spesifikk, kvantitativ bestemmelse av proteiner og andre komponenter i blod og andre vaesker.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: GROSSE, BOCKHORNI, SCHUMACHER, 81476 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: GROSSE, SCHUMACHER, KNAUER, VON HIRSCHHAUSEN, 8033